Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy

VERU INC.

Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.
Novo Nordisk supplies Wegovy at no cost; Veru retains full global rights to enobosarm.
Veru grants Novo Nordisk right of first negotiation if Veru develops enobosarm combo with any Novo GLP-1 product.
Veru provides trial design and safety data insights; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.